Voyager Therapeutics to Present at Canaccord Genuity 44th Annual Growth Conference & Private Company Showcase

Core Insights - Voyager Therapeutics, Inc. is participating in the Canaccord Genuity 44th Annual Growth Conference & Private Company Showcase on August 14, 2024, at 9:30 a.m. ET [1] - The company focuses on advancing neurogenetic medicines aimed at treating neurological diseases [3] Company Overview - Voyager Therapeutics is dedicated to leveraging human genetics to modify and potentially cure neurological diseases, with a pipeline that includes programs for Alzheimer's disease, ALS, Parkinson's disease, and other central nervous system diseases [3] - The company utilizes its TRACER™ AAV capsid discovery platform to generate novel capsids for high brain penetration of genetic medicines following intravenous dosing [3] - Voyager has both wholly owned programs and collaborations with partners such as Alexion, AstraZeneca Rare Disease, Novartis Pharma AG, Neurocrine Biosciences, Inc., and Sangamo Therapeutics, Inc. [3]